Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Angiogenesis is a complex biological process involving the coordinated modulation of many genes. Histone deacetylases (HDAC) are a growing family of enzymes that mediate the availability of chromatin to the transcriptional machinery. Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), two HDAC inhibitors known to relieve gene silencing, were evaluated as potential antiangiogenic agents. TSA and SAHA were shown to prevent vascular endothelial growth factor (VEGF)-stimulated human umbilical cord endothelial cells (HUVEC) from invading a type I collagen gel and forming capillary-like structures. SAHA and TSA inhibited the VEGF-induced formation of a CD31-positive capillary-like network in embryoid bodies and inhibited the VEGF-induced angiogenesis in the CAM assay. TSA also prevented, in a dose-response relationship, the sprouting of capillaries from rat aortic rings. TSA inhibited in a dose-dependent and reversible fashion the VEGF-induced expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1. TSA and SAHA upregulated the expression by HUVEC of semaphorin III, a recently described VEGF competitor, at both mRNA and protein levels. This effect was specific to endothelial cells and was not observed in human fibroblasts neither in vascular smooth muscle cells. These observations provide a conspicuous demonstration that HDAC inhibitors are potent anti-angiogenic factors altering VEGF signaling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhibition of HDAC attenuates VEGF signalling, which is important for vascular morphogenesis and endothelial differentiation [195].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [195]
Citations
Cites
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483 · cited 7×
“…e ect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999), and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999).”
BackgroundInfluentialYoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815 · cited 4×
“HDAC have been associated with a repression of transcription (Struhl, 1998) and their inhibition should relieve gene silencing.”
BackgroundInfluentialAntiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · cited 1×
“Antiangiogenic therapy of cancers o ers the possibility of a low toxicity treatment without acquisition of drug resistance due to the genetic stability, homogeneity and low mutational rate of endothelial cells (Boehm et al., 1997).”
BackgroundA class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914 · cited 2×
“By using speci®c inhibitors, mainly TSA and SAHA (Yoshida et al., 1990; Richon et al., 1998) in di erent models based on in vitro, ex vivo and in vivo assays, we demonstrated that HDAC inhibition suppresses the spontaneous or VEGFinduced angiogenesis.”
BackgroundMethodSelf-citationHistone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731 · cited 7×
“At the time that we were preparing this manuscript, a study reporting the involvement of histone deacetylases in angiogenesis was published by Kim et al. (2001).”
BackgroundMethodInfluentialKijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps
Vittet, D., Prandini, M., Berthier, R., Schweitzer, A., Martin-Sisteron, H., Uzan, G., & Dejana, E. (1996) · Blood · doi:10.1182/blood.v88.9.3424.bloodjournal8893424 · Cited by 472 · cited 1×
“Capillary-like structures formation was analysed by the expression of CD31 in whole mount immuno¯uorescence as reported by Vittet et al. (1996).”
MethodNeuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of Endothelial Cell Motility
Miao, H.-Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., & Klagsbrun, M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.1.233 · Cited by 458 · cited 5×
“…e ect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999), and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999).”
BackgroundInfluentialDeroanne, C. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00233-9 · Cited by 256 · cited 1×
“Culture medium, Oncogene HUVEC were induced to organize into a network of tube-like structures as described (Deroanne et al., 1996, 2001).”
MethodSelf-citation
Cited by
Items 301–400 of 406
Jangra, A., Choi, S. A., Koh, E. J., Moon, Y. J., Wang, K., Phi, J. H., Lee, J. Y., & Kim, S. (2019) · Child s Nervous System · doi:10.1007/s00381-019-04099-y · Cited by 11
Rana, Z., Diermeier, S. D., Walsh, F. P., Hanif, M., Hartinger, C. G., & Rosengren, R. J. (2021) · Pharmaceuticals · doi:10.3390/ph14101020 · Cited by 10
“This concentration was chosen as SAHA was tested at a similar concentration in a previous study, allowing for a direct comparison [58].”
MethodEpigenetic regulations on skin wound healing: implications from current researches.
Zhang, S., & Duan, E. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.07.12 · Cited by 11
“HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid showed anti-angiogenic effect through altering VEGF signaling (16); and VEGF-mediated down-regulation of miR-101 causes angiogenic effects through reduced repression of Ezh2 (17).”
BackgroundHuang, Y., Huang, S.-W., Hsu, Y.-F., Ou, G., Huang, W., & Hsu, M. (2015) · Scientific Reports · doi:10.1038/srep15900 · Cited by 10
Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137)
Simões‐Pires, C. A., Bertrand, P., & Cuendet, M. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1282945 · Cited by 10
Novel therapeutic approaches for cutaneous T cell lymphomas
Pavlidis, A., Piperi, C., & Papadavid, E. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1919085 · Cited by 10
Bai, S., Chen, L., Yan, Y., Wang, X., Jiang, A., Li, R., Kang, H., Feng, Z., Li, G., Ma, W., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.796156 · Cited by 11
“A combination of selumetinib and vorinostat can inhibit proliferation and spheroid formation, which is associated with an increase in apoptosis, cell cycle arrest, and reduced cellular migration and VEGF-A secretion in CRC cells (Deroanne et al., 2002; Morelli et al., 2012).”
BackgroundMahal, K., Kahlen, P., Biersack, B., & Schobert, R. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.06.008 · Cited by 9
Demosthenous, M., Antoniades, C. A., Tousoulis, D., Margaritis, M., Marinou, K., & Stefanadis, C. (2011) · Artery Research · doi:10.1016/j.artres.2011.03.003 · Cited by 12
“Subsequently, it was shown that adenoviral over expression of KLF2 in HUVECS resulted in a dramatic induction of eNOS mRNA, protein, and enzyme activity.(20) Recently, it has been demonstrated that tumor necrosis factor a (TNF-a) also has effect on eNOS transcription.”
BackgroundGoehringer, N., Peng, Y., Nitzsche, B., Biermann, H., Pradhan, R., Schobert, R., Herling, M., Höpfner, M., & Biersack, B. (2021) · Pharmaceuticals · doi:10.3390/ph14121319 · Cited by 9
Nakao, Y., Yoshida, S., Matsunaga, S., Shindoh, N., Terada, Y., Nagai, K., Yamashita, J. K., Ganesan, A., van Soest, R. W. M., & Fusetani, N. (2006) · Angewandte Chemie · doi:10.1002/ange.200602047 · Cited by 9
Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin
Pereira, M. A., Warner, B. M., Knobloch, T. J., Weghorst, C. M., Lubet, R. A., Steele, V. E., & Casto, B. C. (2011) · International Journal of Cancer · doi:10.1002/ijc.27395 · Cited by 9
“These results support the current literature that the chemopreventive activity of SAHA is, in part, related to its antiangiogenic effects.(31) SAHA has also been shown to have an effect on invasion and metastasis pathways in models of breast and prostate cancers.”
ResultZafar, S. F., Nagaraju, G. P., & El‐Rayes, B. F. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.691473 · Cited by 9
“Pan-HDAC inhibitors, TSA and vorinostat, have demonstrated inhibition of vascular endothelial growth factor (VEGF)-induced expression of VEGF receptors VEGFR1 andVEGFR2, as well as upregulate the VEGF competitor protein, semaphorin II [32].”
BackgroundHistone Deacetylase Inhibitors in Cancer Prevention and Therapy
Movafagh, S., & Munson, A. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812494-9.00004-4 · Cited by 12
La régulation de HIF-1α (Hypoxia-Inducible Factor-1α) : un air nouveau dans le domaine de l’hypoxie
Berta, M., Brahimi‐Horn, C., & Pouysségur, J. (2004) · Journal de la Société de Biologie · doi:10.1051/jbio/2004198020113 · Cited by 8
Investigational Approaches for Mesothelioma
Surmont, V. F. M., van Thiel, E. R. E., Vermaelen, K. Y., & van Meerbeeck, J. P. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00022 · Cited by 8
“Therefore, sophisticated treatment techniques, oriented by surgeon’s and pathologist’s findings, are needed (Maasilta, 1991; Senan, 2003).”
BackgroundMethodHistone Deacetylase Inhibitors in APL and Beyond
Petrie, K. R., Prodromou, N. V., & Zelent, A. (2007) · Springer eBooks · doi:10.1007/978-3-540-34594-7_10 · Cited by 8
“Another importantmechanism of action of HDACi is themodulation of genes involved in hypoxia-induced angiogenesis such asVEGF andHIF-1α [51, 176, 233, 234, 281, 301].”
BackgroundFerrocene Derivatives as Histone Deacetylase Inhibitors: Synthesis and Biological Evaluation
Angelova, R., & Stavrakov, G. (2025) · Organics · doi:10.3390/org6010004 · Cited by 6
“The antiproliferative activity of this class of compounds is also linked to their ability to block the formation of cyclin/CDK complexes, inhibit angiogenesis (thereby preventing tumour vascularization), induce autophagy, and modulate the immune response against tumour cells [8–11].”
Effect of valproic acid treatment on penile structure in prepubertal rats
Kutlu, Ö., Cansu, A., Karagüzel, E., Gürgen, S. G., Koç, Ö., Gür, M., & Özgür, G. K. (2012) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.12.010 · Cited by 7
Rodgers, C. D., Sherwood, M. B., Lukowski, Z. L., Min, J., Martorana, G. M., Wilson, M. K., Schaefer, J. L., Levine, M. A., Meyers, C., Blake, C. R., et al. (2019) · JOURNAL OF CURRENT GLAUCOMA PRACTICE · doi:10.5005/jp-journals-10078-1246 · Cited by 6
Development of an angiogenesis-focused cDNA chip and validation of its functionality
Shim, J. S., Lee, H., Park, H. M., Kim, J. O., Kim, E., Hwang, K. H., Kim, K. T., Park, S.-W., Lee, J. H., & Kwon, H. J. (2005) · Experimental & Molecular Medicine · doi:10.1038/emm.2005.46 · Cited by 6
“In the down-regulated genes, VEGFs are known to be decreased by HDAC inhibitors (Kim et al., 2001; Deroanne et al., 2002).”
BackgroundTurunen, T. A., Väänänen, M., & Ylä‐Herttuala, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99575-9 · Cited by 10
Zhou, J., Lim, S. H., & Chiu, J. (2011) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-011-0199-2 · Cited by 5
Angiogenesis and Cardiovascular Diseases: The Emerging Role of HDACs
Moraga, A., Lao, K. H., & Zeng, L. (2017) · InTech eBooks · doi:10.5772/66409 · Cited by 5
“the sprouting of capillaries from rat aorta [35].”
BackgroundRetractedLiu, Y., Mo, J., Guo, Z., Zhang, J., Tang, W., Meng, X., Luo, Y., Wang, F., & Mo, Z. (2025) · Angiogenesis · doi:10.1007/s10456-025-09998-0 · Cited by 4
“Histone deacetylase (HDAC) inhibitors have been shown to inhibit VEGF signaling, preventing HUVEC invasion and capillary structures formed on type-I collagen gel [56].”
Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview
Seane, E. N., Nair, S., Vandevoorde, C., & Joubert, A. M. (2024) · Pharmaceuticals · doi:10.3390/ph17050602 · Cited by 4
Epigenetic Regulation of Skin Wound Healing
Mardaryev, A. N. (2018) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-16769-5_12 · Cited by 4
Zang, X., Peraro, L., Davison, R. T., Blum, T. R., Vallabhaneni, D., Fennell, C. E., Cramer, S. L., Shah, H., Wholly, D. M., Fink, E. A., et al. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c00854 · Cited by 4
Bär, S. I., Dittmer, A., Nitzsche, B., Ter‐Avetisyan, G., Fähling, M., Klefenz, A., Kaps, L., Biersack, B., Schobert, R., & Höpfner, M. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5363 · Cited by 4
“In this respect, HDACis are known to inhibit VEGF-induced angiogenesis in vitro as well as in vivo (71), such that CA-4-driven anti-angiogenesis has also been linked to the inhibition of VEGF (72).”
BackgroundSynthesis and Anticancer Potential of New Hydroxamic Acid Derivatives as Chemotherapeutic Agents
Korkmaz, I. N., & Özdemіr, H. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04107-z · Cited by 6
Ahmadzadeh, V., Tofigh, R., Farajnia, S., & Pouladi, N. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2015.1077830 · Cited by 4
“Histone deacetylase inhibitors, HDACi Recently, more attention has been paid to role of abnormal promoter DNA methylations and histone modifications in the aberrant expression of oncogenes or repression of tumor suppressor genes, whose inhibition patterns are associated with anti-angiogenic activity [125, 126].”
BackgroundNatural Products for Cancer Prevention and Therapy
Bishayee, A., & Yerer-Aycan, M. B. (2018) · MDPI eBooks · doi:10.3390/books978-3-03897-311-9 · Cited by 5
Batalo, M., Bose, P., Holkova, B., & Grant, S. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-06752-0_6 · Cited by 4
“genic effects [177, 178]; generation of the proapoptotic lipid second messenger”
BackgroundHong, S., Chang, S., Yeom, D.-H., Kang, J., & Hong, K. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3281e4429d · Cited by 3
Kumar, D., Sarma, P. N., Bhadra, M. P., & Tangutur, A. D. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190101115034 · Cited by 3
Histone Deacetylase Inhibitors: Novel Targeted Anti-Cancer Agents
Marks, P. A., & Kelly, W. K. (2005) · Springer eBooks · doi:10.1007/1-4020-3642-6_12 · Cited by 3
Shukla, D., Matore, B. W., Murmu, A., Gawande, P., Roy, P. P., & Singh, J. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2605010 · Cited by 2
Epigenetic Targets in Drug Discovery: Cell‐Based Assays for HDAC Inhibitor Hit Validation
Jung, M., Yong, K., Velena, A., & Lee, S. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627073.ch6 · Cited by 3
Regulation of HDACi−Triggered Autophagy by the Tumor Suppressor Protein p53
Mrakovcic, M., & Fröhlich, L. F. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86911 · Cited by 3
Ganai, S. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-8179-3_5 · Cited by 2
The multifactorial role of HDAC9 at the maternal–fetal interface in the pathogenesis of preeclampsia
Opichka, M. A., McIntosh, J. J., & Grobe, J. L. (2025) · Clinical Science · doi:10.1042/cs20242385 · Cited by 1
“Pan HDAC inhibition impaired VEGF-induced angiogenic activity in human umbilical vein endothelial cells (HUVECs), leading to upregulation of the VEGF competitor semaphorin III, and mitigated capillary sprouting from rat aortic rings [211].”
El‐Sehrawy, A. A. M. A., Oriquat, G., Saidov, S., Ruzikulov, U., Shakhmurova, G., Jbl, B. J., Singhal, D., & Shefali (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121066 · Cited by 1
Tuning epigenetics to enhance cancer virotherapy
Wang, Y., Zhang, L., Che, Y., Fu-hua, Y., & Sun, Z. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.045 · Cited by 1
“HDACis also inhibit angiogenesis and metastasis by suppressing vascular endothelial growth factor (VEGF), basic fibroblast growth factor, hypoxia inducible factor 1 α , and endothelial nitric oxide synthase 138 — 140 .”
Lucaciu, R. L., Hangan, A. C., Oprean, L. S., & Procopciuc, L. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198619 · Cited by 1
Zappasodi, R., & Nicola, M. D. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_5 · Cited by 1
Kim, Y. S., Song, Y., & Kwon, H. J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.101 · Cited by 1
Vorinostat for the treatment of cutaneous T-cell lymphoma
Zhang, C., & Duvic, M. A. (2010) · Expert Review of Dermatology · doi:10.1586/edm.10.35 · Cited by 3
Shankar, T. V. S., Sulka, B., Hubert, P., Hubaux, R., Delvenne, P., Pendeville, H., Boittiaux, I., Lambert, D. M., Wouters, J., Maillard, C., et al. (2015) · Journal of Cancer Sciences · doi:10.13188/2377-9292.1000008 · Cited by 1
“Histone deacetylase inhibitors (HDACi) directly inhibit ECs growth and tumor angiogenesis by modifying the balance between pro- and anti-angiogenic factors [15,17-20].”
BackgroundSelf-citationResveratrol as an Angiogenesis Inhibitor
Bråkenhielm, E., Cao, Y., & Cao, Y. (2005) · CRC Press eBooks · doi:10.1201/9781420026474-9 · Cited by 1
Hydroxamic Acids as Potent Antioxidants and Their Methods of Evaluation
Mehndiratta, S., Nepali, K., & Satapathy, M. K. (2017) · Springer eBooks · doi:10.1007/978-981-10-4711-4_5 · Cited by 1
Guo, S. (2011) · Wiley eBooks · doi:10.1002/9781444398519.ch7 · Cited by 1
Enzyme Inhibitors from Marine Invertebrates
Nakao, Y., & Fusetani, N. (2012) · Springer eBooks · doi:10.1007/978-90-481-3834-0_23 · Cited by 2
Valproic acid and bladder healing: an experimental study in rats
Biondo-Simões, M. D. L. P., DALL’ANTONIA, M. O., GOEHR, M. P., Biondo-Simões, R., Ioshii, S. O., & Robes, R. R. (2022) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20223399 · Cited by 1
Ryu, H. E., Yoon, J., Choi, J., Heo, S., Hong, K., & Jung, D. (2024) · Vaccines · doi:10.3390/vaccines12060626 · Cited by 1
“Studies have indicated anti-tumor effects, such as the inhibition of cell growth and differentiation, reduction in angiogenesis, and induction of cell apoptosis, when commonly overexpressed HDACs in cancer are inhibited [34–36].”
BackgroundRoles of Cytoplasmic Deacetylase Hdac6 in Oncogenic Tumorigenesis
Lee, Y. (2008) · DukeSpace (Duke University)
Epigenetic Modifiers to Augment the Immunogenicity of Chronic Lymphocytic Leukemia
Dubovsky, J. A. (2013) · Digital Commons - University of South Florida (University of South Florida)
Engineering Herpes Simplex Virus for Cancer Oncolytic Virotherapy
Buhrman, J. S., Cheema, T. A., & Fulci, G. (2010) · Wiley eBooks · doi:10.1002/9780470626528.ch7
Pharmaco-Epigenomics to Improve Cancer Therapies
Claes, B., Siebens, B., & Lambrechts, D. (2012) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.201100026
Liu, T. (2007) · VTechWorks (Virginia Tech)
Investigating breast cancer metastasis to brain in pre-clinical mouse models of metastasis
Kim, S. (2015) · Minerva Access (University of Melbourne)
Targeting Histone Deacetylases in Melanoma and T-cells to Improve Cancer Immunotherapy
Laino, A. S. (2016) · Digital Commons - University of South Florida (University of South Florida)
Epigenetic mechanisms in development, inheritance and disease
Bollen, M., Minnebo, N., & Eynde, A. V. (2012) · Cited by 1
Protecting the Endothelial Cell Barrier
Joshi, A., & Catravas, J. D. (2015) · Journal of Cell Science & Therapy · doi:10.4172/2157-7013.1000e120
“HDAC inhibitors suppress LPS-mediated TLR4 signaling [33], eNOS mRNA and protein levels [34,35], induce angiogenesis [36] and suppress thrombin-induced EBD [37].”
BackgroundThe Value of Anti-angiogenics in Multiple Myeloma Therapy
Moehler, T. M., Hose, D., Andrulis, M., Seckinger, A., & Goldschmidt, H. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_34
Gonzalez, A. (2014) · ORBi (University of Liège)
Epigenetic Targeting of Vascular Endothelial Growth Factor (VEGF) Receptors
Gray, S. G. (2019) · Springer eBooks · doi:10.1007/978-3-319-55530-0_36
Woan, K. V. (2012) · University of Florida Digital Collections (University of Florida)
Discovery Of Piperlongumine Derivatives As Anti-Leukemic And Anti-Prostate Cancer Agents
Liao, Y. (2018) · Human Biology
Regulation of promyelocytic leukemia protein expression
Dobrovolná, J. (2008) · Digital Repository (National Repository of Grey Literature)
Targeting (de)acetylation: A Diversity of Mechanism and Disease
Quaas, C. E., & Long, D. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00076-1
Epigenetic insights for wound healing mechanism
Sharma, A. K., Kalonia, A., Shaw, P., & Shukla, S. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85652-2.00016-6
Epigenetic regulation of tumor angiogenesis
Hellebrekers, D. M. E. I. (2006) · Research Publications (Maastricht University) · doi:10.26481/dis.20061102dh
Impacto de los inhibidores de Deacetilasas de Histonas (iHDAC) sobre la funcionalidad de células NK
Rossi, L. E. (2012) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Endometriosis Research: From Bench to Bedside
Laganà, A. S., & Rosa, V. L. L. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2798-7
The Value of Anti-Angiogenics in Multiple Myeloma Therapy
Moehler, T. M., Hose, D., Andrulis, M., Seckinger, A., & Goldschmidt, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-31215-6_34-1
Full PDF of Hematology Reviews 2009, volume 1, issue 1.
Editors, T. L. O. (2011) · Hematology Reports · doi:10.4081/1716 · Cited by 1
Ylä-Herttuala, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99575-8
Epigenetic Targeting of Vascular Endothelial Growth Factor (VEGF) Receptors
Gray, S. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_36-1
Rysavka, P., & Lánová, M. K. (2018) · Praktické lékárenství · doi:10.36290/lek.2018.014
Effect of Trichostatin A on Bleomycin Induced Pulmonary Fibrosis in Mice and its Mechanism
Zhang, Q., Guo, Z. X., Zhang, J., Yang, D. L., Jiang, P., Cao, J., & Li, S. (2023) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.spl.630
Yang, Q., Tian, Y., Liu, S., Zeine, R. R., Chlenski, A., Salwen, H. R., Henkin, J., & Cohn, S. L. (2023) · doi:10.1158/0008-5472.c.6494820
Yang, Q., Tian, Y., Liu, S., Zeine, R. R., Chlenski, A., Salwen, H. R., Henkin, J., & Cohn, S. L. (2023) · doi:10.1158/0008-5472.c.6494820.v1
Data from Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant Cells
Ma, X., Liu, J., Wu, J., Yan, X., Wu, P., Liu, Y., Li, S., Tian, Y., Cao, Y., Chen, G., et al. (2023) · doi:10.1158/1078-0432.c.6519086
Morita, A., Takahashi, K., Iizuka, N., & Nakahara, T. (2025) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2025.09.005
Differentiation Agents and Epigenomic Therapies: An Overview and Potential Use for Prostate Cancer
Kortenhorst, M. S. Q., Carducci, M. A., & Shabbeer, S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-224-3_22
Clinical Significance of Histone Deacetylase Inhibitors in Cancer
Shankar, S., & Srivastava, R. K. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-200-7_15
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786888
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786882
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786891
Zhu, S., Zhu, W., Zhao, K., Yu, J., Lu, W., Zhou, R., Fan, S., Kong, W., Yang, F., & Shan, P. (2024) · Figshare · doi:10.6084/m9.figshare.26309066
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786885
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786894
Zhu, S., Zhu, W., Zhao, K., Yu, J., Lu, W., Zhou, R., Fan, S., Kong, W., Yang, F., & Shan, P. (2024) · Figshare · doi:10.6084/m9.figshare.26308916
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786897
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suarez-Alvarez, B. (2021) · Figshare · doi:10.6084/m9.figshare.16786900
Franforte, E. (2019) · Institutional Research Information System (University of Udine)
HDAC4: studying the pro-oncogenic role in human immortalized fibroblasts
Gagliostro, E. (2016) · Institutional Research Information System (University of Udine)
(2015) · Institutional Research Information System (University of Udine)
Epigenetics in angiogenesis, gastrointestinal cancer progression and its clinical significance
Chandana, A. N., & Bhagya, N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27765-8.00012-6
Metadata
- Authors
- Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., & Castronovo, V.
- Affiliations
- University of Liège (BE)
- University of California, San Francisco (US)
- Corresponding author
- Deroanne, Christophe F
- Venue
- Oncogene
- Published
- 2002-01-17
- Volume
- 21
- Issue
- 3
- Pages
- 427-436
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2031671750
- Cited by
- 400
- References
- 25
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 24 · 2020: 11 · 2019: 16 · 2018: 10 · 2017: 18 · 2016: 18 · 2015: 18 · 2014: 20 · 2013: 15 · 2012: 27
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- histone deacetylase inhibitors, trichostatin A, vorinostat, angiogenesis inhibitors, VEGF signaling, VEGF receptors, VEGFR1, VEGFR2, neuropilin-1, human umbilical vein endothelial cells, capillary formation, angiogenesis, chromatin remodeling
- MeSH terms
- Vorinostat, Animals, Aorta, Carrier Proteins, Cells, Cultured, Chick Embryo, Chorion, Endothelium, Vascular, Histone Deacetylases, Humans, Hydroxamic Acids, Lymphokines, Microscopy, Fluorescence, Microscopy, Phase-Contrast, Nerve Tissue Proteins, RNA, Messenger, RNA, Ribosomal, 28S, Umbilical Veins, Blotting, Western, Signal Transduction, Up-Regulation, Endothelial Growth Factors, Reverse Transcriptase Polymerase Chain Reaction, Angiogenesis Inhibitors, Semaphorin-3A, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Rats, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.